Elicera Therapeutics advances ELC-301 into Phase IIa at highest dose in B-cell lymphoma trial
Reuters2026/09/09 06:46- Elicera Therapeutics will advance ELC-301 into Phase IIa in its CARMA study in B-cell lymphoma, using the highest tested dose.
- The trial’s safety panel backed the dose selection with no major safety issues reported in the completed Phase I portion.
- Earlier interim results were already presented, showing broad disease control with many patients achieving tumor shrinkage, including some reaching disease-free status.
- The company plans to present preliminary Phase I efficacy results for all 12 patients once the last patient completes a one-month assessment.
- Phase IIa dosing is expected to start once Sweden’s Medical Products Agency clears the protocol to proceed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Paramount Seeks Bond Over Merger Delay
Regency Silver agrees to buy Tarachi Gold, adding Jabali Gold Project in Mexico
Mutares completes sale of NEM Energy Group to Hyundai Heavy Industries Power Systems
AI marketing platform Braze (BRZE.US) reports strong earnings, but shares plunge after hours! Q2 revenue and EPS both exceed expectations, annual guidance raised
Artificial intelligence (AI) marketing platform Braze reported better-than-expected results for the second fiscal quarter and raised its full-year guidance for fiscal year 2027.
Crypto prices
More
